AI-generated · cited to primary sources · not investment advice
Anthem Bioscienc (544449) Feb 2026 Filing Analysis
Does management do what it says?
The company reported EBITDA margins of 44.5% for Q2FY26 and 41.4% for H1FY26, significantly exceeding the 38% target range. (5 exceeded across 5 tracked commitments)
“In terms of revenue growth, it will be in the mid-teens around 15% to 16% is what we will be anticipating to end the year with.”
See the full cited Management analysis of Anthem Bioscienc
How durable is the business?
The company is deepening its expertise in high-barrier areas, specifically mentioning 8-9 innovator programs in peptides and the development of a microbial biosimilar for a US customer. (2 expanding)
“4 molecules went commercial. So, still at 6 [in Phase-3]... We currently work with innovator peptides, close to about 8-9 programs.”
See the full cited Business Model analysis of Anthem Bioscienc
Where does growth come from?
The Phase 3 pipeline is steady with 6 molecules remaining after 4 successfully transitioned to commercial status. The early-stage pipeline remains robust with 130-140 molecules. (1 steady across 1 signal)
“4 molecules went commercial. So, still at 6... the pipeline on early stage is still robust.”
See the full cited Future Growth analysis of Anthem Bioscienc
What could break the thesis?
Margins are actually improving and showing structural resilience due to successful backward integration and the discontinuation of expensive Chinese intermediate supplies. (3 easing)
“What had happened over the course of this financial year is, we have completely discontinued China supplies because now we manufacture the intermediate in-house... so we are completely backward integrated.”
See the full cited Risk analysis of Anthem Bioscienc
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.